Monitoring of JAK2V617F allele burden in patients with essential thrombocythemia
Blood Research · 2026-12 · 61 (1)
DOI: 10.1007/s44313-026-00137-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Research, online erschienen am 22.04.2026. Verfasst von Jeong Suk Koh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, 282 Munhwa-Ro, Jung-Gu, Daejeon, …. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chungnam National University.
Abstract (Originalsprache)
Background/Aim This study retrospectively examined the clinical implications of monitoring JAK2 V617F, with a particular focus on disease transformation, in a Korean population of patients with essential thrombocythemia (ET).
Methods
Medical records of patients diagnosed with ET between January 1996 and December 2021 at Chungnam National University Hospital, Daejeon, Korea, were reviewed. Both episodic changes (increase or decrease) and longitudinal patterns of change (stable, gradual increase, or gradual decrease) in JAK2 V617F variant allele frequency (VAF), measured at 1-year intervals, were analyzed.
Results
Among the 87 patients who had JAK2 V617F VAF measured at least three times, 23 (26.4%), 21 (24.1%), and 16 (18.4%) experienced increases of ≥ 25%, ≥ 50%, and ≥ 100%, respectively, while 27 (42.5%), 26 (29.9%), and 2 (2.3%) experienced decreases of ≥ 25%, ≥ 50%, and 100%, respectively. Patients with VAF increases had significantly poorer transformation-free survival than those without increases (15-year survival for ≥ 50% increase: 79.2% vs. 97.5%; p = 0.007). Regarding the longitudinal patterns, 62 (71.3%), 13 (14.9%), and 12 (13.8%) patients were classified as having stable, gradual increase, and gradual decrease patterns, respectively. Transformation-free survival was worse in patients with a gradual increase and better in those with a gradual decrease than in those with a stable pattern (20-year survival: 100% vs. 88.8% vs. 31.3%; p = 0.026).
Conclusions
An increasing JAK2 V617F allele burden over time is associated with disease transformation in ET, supporting the need for the ongoing monitoring of JAK2 V617F VAF in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Korea.
- Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, 282 Munhwa-Ro, Jung-Gu, Daejeon, 35015, Korea. deogyeon@cnu.ac.kr.
Förderung
- Chungnam National University
Zitieren
APA
Koh, J. S., Seo, W., Kang, S., Lee, M. W., Ryu, H., Baek, S. W., Song, I. C., Lee, H. J., & Jo, D. Y. (2026). Monitoring of JAK2V617F allele burden in patients with essential thrombocythemia. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00137-2
Vancouver
Koh JS, Seo W, Kang S, Lee MW, Ryu H, Baek SW, et al. Monitoring of JAK2V617F allele burden in patients with essential thrombocythemia. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00137-2
BibTeX
@article{Koh2026,
author = {Koh, Jeong Suk and Seo, Wonhyoung and Kang, Sora and Lee, Myung-Won and Ryu, Hyewon and Baek, Seung-Woo and Song, Ik-Chan and Lee, Hyo-Jin and Jo, Deog-Yeon},
title = {Monitoring of JAK2V617F allele burden in patients with essential thrombocythemia},
journal = {Blood Research},
year = {2026},
volume = {61},
number = {1},
doi = {10.1007/s44313-026-00137-2}
}
EUVIMED